Xu XY - Search Results

1

Delivery of Protein Kinase A by CRISPRMAX and Its Effects on Breast Cancer Stem-Like Properties.

Zhou JN, Rautio TC, Liu C, Xu XY, Wang DQ, Guo Y, Eriksson J, Zhang H. Zhou JN, et al. Among authors: xu xy. Pharmaceutics. 2020 Dec 23;13(1):11. doi: 10.3390/pharmaceutics13010011. Pharmaceutics. 2020. PMID: 33374889 Free PMC article.

2

Mineralization of pH-Sensitive Doxorubicin Prodrug in ZIF-8 to Enable Targeted Delivery to Solid Tumors.

Yan J, Liu C, Wu Q, Zhou J, Xu X, Zhang L, Wang D, Yang F, Zhang H. Yan J, et al. Anal Chem. 2020 Aug 18;92(16):11453-11461. doi: 10.1021/acs.analchem.0c02599. Epub 2020 Jul 27. Anal Chem. 2020. PMID: 32664723 Free PMC article.

3

Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer.

Liang Y, Wang Y, Wang L, Liang Z, Li D, Xu X, Chen Y, Yang X, Zhang H, Niu H. Liang Y, et al. Bioact Mater. 2020 Sep 8;6(2):433-446. doi: 10.1016/j.bioactmat.2020.08.019. eCollection 2021 Feb. Bioact Mater. 2020. PMID: 32995671 Free PMC article.

4

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.

Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Xu X, et al. Adv Drug Deliv Rev. 2021 Sep;176:113891. doi: 10.1016/j.addr.2021.113891. Epub 2021 Jul 26. Adv Drug Deliv Rev. 2021. PMID: 34324887 Free article. Review.

5

Improving the knock-in efficiency of the MOF-encapsulated CRISPR/Cas9 system through controllable embedding structures.

Liu C, Xu X, Koivisto O, Zhou W, Jacquemet G, Rosenholm JM, Zhang H. Liu C, et al. Nanoscale. 2021 Oct 14;13(39):16525-16532. doi: 10.1039/d1nr02872c. Nanoscale. 2021. PMID: 34596650

6

The potential role of hsa_circ_0001079 in androgenetic alopecia via sponging hsa-miR-136-5p.

Wei H, Xu X, Yang S, Liu C, Li Q, Jin P. Wei H, et al. J Clin Lab Anal. 2022 Jan;36(1):e24021. doi: 10.1002/jcla.24021. Epub 2021 Nov 17. J Clin Lab Anal. 2022. PMID: 34788492 Free PMC article.

7

Fabrication of a pH/Redox-Triggered Mesoporous Silica-Based Nanoparticle with Microfluidics for Anticancer Drugs Doxorubicin and Paclitaxel Codelivery.

Yan J, Xu X, Zhou J, Liu C, Zhang L, Wang D, Yang F, Zhang H. Yan J, et al. ACS Appl Bio Mater. 2020 Feb 17;3(2):1216-1225. doi: 10.1021/acsabm.9b01111. Epub 2020 Jan 27. ACS Appl Bio Mater. 2020. PMID: 35019322

8

In Vivo Kidney Allograft Endothelial Specific Scavengers for On-Site Inflammation Reduction under Antibody-Mediated Rejection.

Liu C, Yan P, Xu X, Zhou W, Prakash DR, Wang S, Zhou J, Wang R, Huang H, Chen J, Zhang H, Shen J. Liu C, et al. Small. 2022 Sep;18(36):e2106746. doi: 10.1002/smll.202106746. Epub 2022 Mar 2. Small. 2022. PMID: 35235710

9

Microfluidic-assisted biomineralization of CRISPR/Cas9 in near-infrared responsive metal-organic frameworks for programmable gene-editing.

Xu X, Liu C, Wang S, Mäkilä E, Wang J, Koivisto O, Zhou J, Rosenholm JM, Shu Y, Zhang H. Xu X, et al. Nanoscale. 2022 Nov 3;14(42):15832-15844. doi: 10.1039/d2nr04095f. Nanoscale. 2022. PMID: 36255392 Free article.

10

Metabolism-Regulating Nanozyme System for Advanced Nanocatalytic Cancer Therapy.

Liu C, Xu X, Chen Y, Yin M, Mäkilä E, Zhou W, Su W, Zhang H. Liu C, et al. Small. 2024 Jun;20(24):e2307794. doi: 10.1002/smll.202307794. Epub 2024 Jan 2. Small. 2024. PMID: 38168483

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,501 results

Search Page

Filters